21 May 2013
Keywords: boeh, ing, viramune, may, cut, cv, risk
Article | 06 August 2007
Encouraging new data from two studies of Boehringer Ingelheim's Viramune (nevirapine) were presented at the 4th International AIDS Society
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
6 August 2007
20 May 2013
© 2013 thepharmaletter.com